Paclitaxel is under clinical development by PanTher Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Paclitaxel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel overview
Paclitaxel (PTM-101) is under development for the treatment of pancreatic ductal adenocarcinoma. The drug candidate is a drug-eluting matrix enabling the release of already approved cytotoxic agents directly into tumor masses. It acts by targeting tubulin.
PanTher Therapeutics overview
PanTher Therapeutics provides physicians and patients with enabling technologies to offer localized cancer therapies. The company is headquartered in Cambridge, Massachusetts, the US
For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.